US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% GOOGL $324.89 ▲+1.34% NVDA $215.38 ▼-1.17% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.81 +0.23 (+1.58%)
Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
Via Chartmill
Most active stocks in Tuesday's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump ↗
Via Chartmill
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market ↗
Via Chartmill
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
Via Chartmill
News headline image
Why Iovance Biotherapeutics Stock Was on Fire Today ↗
An influential investment bank resumed its coverage of the company. 
Via The Motley Fool
News headline image
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains ↗
Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter... 
Via MarketBeat
News headline image
Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗
Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy. 
Via The Motley Fool
Topics Earnings
News headline image
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗
The healthcare stock is now up more than 130% this year. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Q2 Earnings Call Highlights ↗
Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded... 
Via MarketBeat
Topics Earnings
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results ↗
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should... 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
This Stock Is Up 74% This Year: Is It Too Late to Buy? ↗
The biotech is clearly innovative, but sometimes that's not enough. 
Via The Motley Fool
News headline image
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds. 
Via The Motley Fool
News headline image
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
Tread carefully, but certain factors make this speculative biotech play stand out. 
Via The Motley Fool
News headline image
Iovance (IOVA) Q1 2026 Earnings Transcript ↗
Iovance (IOVA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street ↗
It could just as well drop by 50% -- or more -- over the next 12 months. 
Via The Motley Fool
Topics Death
News headline image
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? ↗
This oncology specialist has proven innovative abilities. 
Via The Motley Fool
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
Via MarketBeat
News headline image
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
If you decide to invest in this company, it's probably best to start small. 
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases. 
Via Stocktwits
News headline image
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized. 
Via Stocktwits
Topics Earnings
Curious about the most active stocks on Tuesday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
Iovance (IOVA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >